Evidence map›Paper›PMID 20371611›Full record

ArticleThe Journal of biological chemistry2010

Identification of heterogeneous nuclear ribonucleoprotein K as a transactivator for human low density lipoprotein receptor gene transcription.

Hai Li, Jingwen Liu

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Therapeutic targets of hypercholesterolemia: HMGCR and LDLR.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hai LiDepartment of Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA.
Jingwen Liu
VA Palo Alto Health Care System · US

Funding

Regulation of Liver LDL Receptor Expression by BerberineR01AT002543 · NCCIH · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI LIU, JINGWEN · 2005 to 2009
$1.7M
Statin-Berberine Combination Therapy in HyperlipidemiaR21AT003195 · NCCIH · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI LIU, JINGWEN · 2008 to 2009
$385k
NCCIH NIH HHS 1R01 AT002543-01A1NCCIH NIH HHS 1R21AT003195-01A2NCCIH NIH HHS R01 AT002543NCCIH NIH HHS R21 AT003195
6 · The paper itself

Abstract

hnRNP K, a member of the family of heterogeneous ribonucleoproteins, is known to exert various functional roles in the nucleus, cytoplasm, and mitochondria to affect different cellular processes including chromatin remodeling, transcription, splicing, and translation. Here we report, for the first time, that hnRNP K is specifically involved in human LDL receptor (LDLR) gene transcription in HepG2 cells. We show that depletion of hnRNP K by siRNA transfection reduces the expression of LDLR mRNA and protein by more than 50% as measured by quantitative real-time PCR and Western blot analysis. Importantly, we show that the decay rate of LDLR mRNA is not affected by hnRNP K siRNA transfection, whereas the LDLR promoter activity is significantly decreased. Furthermore, overexpression of hnRNP K increased the LDLR promoter activity by the luciferase reporter assay. By utilizing a series of mutational and deletional constructs of LDLR promoter luciferase reporters, we mapped the K-responsive element to the repeat 3 (R3) sequence of the LDLR promoter. Electrophoretic mobility shift assays show that the K protein binds to a single-stranded DNA probe containing the CT-rich element of R3, which is in contrast to the requirement of double-stranded DNA for Sp1 to bind to R3. Finally, chromatin immunoprecipitation assays reveal a direct interaction of hnRNP K with the LDLR promoter in intact HepG2 cells. These new findings provide strong evidence demonstrating that hnRNP K is an important transactivator for human LDLR gene transcription. This work sheds new light on our current understanding of how LDLR gene expression is controlled at the transcriptional level.

Indexed as

Transcriptional ActivationTranscription, GeneticAcetylationCell Line, TumorChromatin ImmunoprecipitationDactinomycinDNA Mutational AnalysisHeterogeneous-Nuclear Ribonucleoprotein KHistonesHumansModels, GeneticPromoter Regions, GeneticReceptors, LDLRNA, Small InterferingTransfectionDactinomycinHeterogeneous-Nuclear Ribonucleoprotein KHistonesReceptors, LDLRNA, Small Interfering

Identifiers

PMID20371611
PMCPMC2878543
OpenAlexW2008511275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.